TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Program evaLuating the Autoimmune Disease iNvEstigational Drug cT-p13 in AS Patients(PLANETAS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosed with active ankylosing spondylitis~* BASDAI score ≥ 4 and visual analogue scale(VAS) score of spinal pain ≥ 4~Exclusion Criteria:~* have total ankylosing of spine~* have allergies to infliximab~* serious infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- CT-P13 (Type: ACTIVE_COMPARATOR): infliximab
- Remicade (Type: ACTIVE_COMPARATOR): infliximab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of BCX7353 as a Treatment for Attacks of Hereditary Angioedema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Able to provide written, informed consent.~2. A clinical diagnosis of hereditary angioedema Type 1 or Type 2 as documented at any time in the medical records or at the screening visit.~3. Access to and ability to use standard of care acute attack treatment for attacks of HAE.~4. Sexually active women of child-bearing potential and sexually active men must utilize effective contraception.~Exclusion Criteria:~1. Women who are pregnant or breast-feeding.~2. Any clinical condition or medical history that would interfere with the subject's safety or ability to participate in the study.~3. Use of C1INH, androgens or tranexamic acid for prophylaxis of HAE attacks.~4. History of or current alcohol or drug abuse.~5. Infection with hepatitis B, hepatitis C or HIV.~6. Participation in any other investigational drug study currently or within the last 30 days.~7. Positive drugs of abuse screen (unless as used as medical treatment, e.g., with a prescription).~8. An immediate family relationship to either Sponsor employees, the Investigator or employees of the study site.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Part1: BCX7353 750 mg (Type: EXPERIMENTAL): None
- Part 2: BCX7353 500 mg (Type: EXPERIMENTAL): None
- Part 3: BCX7353 250 mg (Type: EXPERIMENTAL): None
- Parts 1, 2 and 3: placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Muscle Fatigue and Scapular Sensorimotor System

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* no shoulder, cervical, and thoracic spine pain within six months~* negative for subacromial impingement test~* normal range of motion of glenohumeral joint~Exclusion Criteria:~* history of dislocation, fracture, or surgery of shoulder joint~* history of central nervous system disorder, rheumatoid arthritis, shoulder osteoarthritis, or cervical radiculopathy

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose or Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria include:~* Subjects having IDA caused by different aetiologies~* Haemoglobin (Hb) ≤ 11 g/dL~* Body weight \> 50 kg~* Serum ferritin (S-ferritin) \< 100 ng/mL~* Estimated Glomerular Filtration Rate (eGFR) ≥ 65 mL/min/1.73 m2~* Serum phosphate (S-phosphate) \> 2.5 mg/dL~* Intolerance or unresponsiveness to oral iron~* Willingness to participate and signing the Informed Consent Form (ICF)~Exclusion criteria include:~* Acute bleeding \> 500 mL within 72 hours~* Anaemia predominantly caused by factors other than IDA~* Hemochromatosis or other iron storage disorders~* Previous serious hypersensitivity reactions to any IV iron compounds~* Treatment with IV iron within the last 30 days prior to screening~* Treatment with erythropoietin or erythropoietin-stimulation agents~* Red blood cell transfusion, radiotherapy, and/or chemotherapy~* Received an investigational drug within the last 30 days prior to screening~* Planned surgical procedure within the trial period~* Hepatic enzymes \> 3 times upper limit of normal~* Surgery under anaesthetic within the last 30 days prior to screening~* Any non-viral infection within the last 30 days prior to screening~* Alcohol or drug abuse within the past 6 months~* Vitamin D deficiency~* Untreated hyperparathyroidism~* Kidney transplantation~* Active malignant disease, disease-free for less than 5 years~* History of a psychological illness or seizures~* Pregnant or nursing women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Iron isomaltoside/ferric derisomaltose (Type: EXPERIMENTAL): Administered IV
- Ferric carboxymaltose (Type: ACTIVE_COMPARATOR): Administered IV

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ketamine Infusion for Social Anxiety Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult between the ages of 18 and 65 years~2. Meet DSM IV criteria for Social Anxiety Disorder by structured clinical interview (SCID) and have a LSAS \>60 with or without co-morbid MDD~Exclusion Criteria:~1. Positive pregnancy test~2. History of substance abuse disorder within the last 6 months or positive urine toxicology on screening (within the previous 6 months).~3. History of pervasive developmental disorder or psychotic disorder by DSM-IV-TR criteria~4. Medical comorbidity that significantly increases the risks associated with ketamine infusion (e.g. untreated hypertension, significant cardiovascular disease)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Ketamine infusion (Type: EXPERIMENTAL): A ketamine infusion was given on day 0 (28) at a dose of 0.5mg/kg over 40 minutes. Assessments were conducted pre-infusion, 3-h post-infusion, and days 1 (1+28), 2 (2+28), 3 (3+28), 5 (5+28), 7 (7+28), 10 (10+28) and 14 (14+28) post-infusion.
- Saline infusion (Type: EXPERIMENTAL): A saline infusion was given on day 0 (28) at a dose of 0.5mg/kg over 40 minutes. Assessments were conducted pre-infusion, 3-h post-infusion, and days 1 (1+28), 2 (2+28), 3 (3+28), 5 (5+28), 7 (7+28), 10 (10+28) and 14 (14+28) post-infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A 17-Week Trial To Assess Pregabalin For The Treatment Of Nerve Pain Due To Spinal Cord Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with nerve pain after Spinal cord injury (traumatic, diving, ischemic and after removal of benign tumors (except meningioma and fibromas)~* Pain has to be chronic(continuous for at least 3 months or intermittent for at least 6 months~* Pain score at least 4 in 4 of 7 days prior to receive treatment.~Exclusion Criteria:~* Pregabalin use in the last 60 days, prior intolerance to pregabalin~* Creatinine clearance \<60 mL/min.~* White blood cell count \<2500/mm3; neutrophil count \<1500/mm3; platelet count \<100 x 103/ mm3.~* Abuse of drugs or alcohol~* Unstable medial conditions~* Clinically significant abnormal electrocardiogram (ECG).~* Presence of severe pain associated with conditions other than spinal cord injury that could confound the assessment or self-evaluation of pain due to spinal cord injury.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- matched placebo (Type: PLACEBO_COMPARATOR): None
- pregabalin (Type: EXPERIMENTAL): flexible dosing over 4 weeks followed by 12 weeks maintenance and one week taper period

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Plant Cell Expressed Recombinant Human Glucocerebrosidase Extension Trial

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Successful completion of Protocol PB-06-001~* The patient signs informed consent~Exclusion Criteria:~* Currently taking another experimental drug for any condition~* Presence of severe neurological signs and symptoms, defined as complete ocular paralysis, overt myoclonus or history of seizures, characteristic of neuronopathic Gaucher disease~* Pregnant or nursing~* Presence of any medical, emotional, behavioral or psychological condition that in the judgment of the Investigator would interfere with the patient's compliance with the requirements of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Naive 30 Units/kg (Type: EXPERIMENTAL): Continue taliglucerase alfa treatment from PB-06-001 (NCT00376168)
- Naive 60 Units/kg (Type: EXPERIMENTAL): Continue taliglucerase alfa treatment from PB-06-001 (NCT00376168)
- Switchover (Type: EXPERIMENTAL): Continue taliglucerase alfa treatment from PB-06-002 (NCT00712348)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: CMV Antiviral Prevention Strategies in D+R-Liver Transplants (CAPSIL)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Be \> / = 18 years of age.~2. Have negative Cytomegalovirus (CMV) serology (confirmed within 6 months of transplant) and receive a liver from a donor with positive CMV serology (R-/D+).~3. Have received their first orthotopic liver transplant (the transplanted liver may be deceased donor or live donor graft) within 10 days prior.~4. Have absolute neutrophil count \> 1000/µL at randomization.~5. - If female, and not postmenopausal or surgically sterile, must have negative pregnancy test (serum or urine) within 48 hours prior to randomization and must also agree to use medically approved method of contraception. Acceptable methods include: barrier method, intrauterine device (hormonal or non-hormonal), oral hormonal contraceptives, abstinence for 100 days after randomization and 3 months after valganciclovir cessation.~   -- If male, and has not had a vasectomy, he must agree to practice barrier method of contraception for 100 days after randomization and 3 months after valganciclovir cessation.~6. Subject or legally authorized representative has provided written informed consent.~Exclusion Criteria:~1. Currently enrolled in any interventional trial of an investigational therapeutic agent unless co-enrollment has been approved by study Principal Investigators (PIs) and the DMID prior to enrollment.~2. Have hypersensitivity to acyclovir, ganciclovir or valganciclovir.~3. Be breast-feeding mother.~4. Have known Human immunodeficiency virus (HIV) infection (based on testing performed during the transplant evaluation process).~5. Be undergoing multi organ transplant or have undergone prior organ transplant.~6. Have expected life expectancy of less than 72 hours.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Preemptive Therapy (Type: EXPERIMENTAL): 900 mg of Valganciclovir given orally twice daily to Preemptive Therapy subjects upon detection of CMV viremia until plasma PCR is negative on two consecutive weekly PCR test. All dosages adjusted for renal dysfunction. n=88
- Prophylaxis (Type: ACTIVE_COMPARATOR): 900 mg of Valganciclovir given orally once daily to subjects for 100 days post transplantation. All dosages adjusted for renal dysfunction. n=88

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-Term Effects of Insulin Plus Metformin Regimens on the Overall and Postprandial Glycemic Control of Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Have type 2 diabetes (World Health Organization \[WHO\] classification~* Have used one or more of the following oral anti-hyperglycemic medications-metformin or second-generation sulfonylurea (for example, glibenclamide, glyburide, glipizide, gliclazide, glimepiride) alone or in combination with one or two insulin injections per day for at least 3 months immediately prior to entering the study. Patients using more than 2 insulin injections per day or subcutaneous insulin infusion prior to the study will not be eligible to participate.~* Have a hemoglobin A1c between 6.5% and 11%, inclusive, according to the central laboratory at Visit 1.~* Have clinically acceptable LDL-C, in the investigator's opinion, at Visit 1.~* As determined by the investigator, are capable and willing to learn how to use the insulin injection pens; comply with their prescribed diet, exercise, and medication regimen; perform self-monitoring of blood glucose; and use the patient diary as required for this protocol.~Exclusion Criteria:~* Have hypersensitivity to metformin or a known allergy to metformin hydrochloride, insulin lispro MM, insulin lispro LM, or insulin glargine, or excipients contained in these products.~* Have known metabolic or lactic acidosis.~* Have a history of renal transplantation or are currently receiving renal dialysis or have serum creatinine greater than or equal to 135 micromol/L (1.5 mg/dL) for males and greater than or equal to 110 micromol/L (1.2 mg/dL) for females.~* Have cardiac disease with functional status that is Class III or IV~* Have obvious clinical signs or symptoms of liver disease, acute or chronic hepatitis, or alanine transaminase (ALT) greater than three times the upper limit of the reference range as defined by the central laboratory.

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed, unresectable locally advanced or metastatic transitional cell carcinoma of the urothelium~* Stage IV disease at the start of first-line chemotherapy~* Measurable disease (per RECIST v1.1) prior to the start of first-line chemotherapy~* Prior first-line chemotherapy must have consisted of at least 4 cycles and no more than 6 cycles of gemcitabine + cisplatin and/or gemcitabine + carboplatin~* No evidence of progressive disease following completion of first-line chemotherapy (i.e., ongoing CR, PR, or SD per RECIST v1.1 guidelines )~Exclusion Criteria:~* Prior adjuvant or neoadjuvant systemic therapy within 12 months of randomization~* Prior immunotherapy with IL-2, IFN-α, or an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or CTLA 4 antibody (including ipilimumab), or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways~* Persisting toxicity related to prior therapy (Grade \>1 NCI CTCAE v4.0); however, alopecia, sensory neuropathy (Grade 2 or less), or other (Grade 2 or less) adverse events not constituting a safety risk based on the investigator's judgement are acceptable.~* Patients with known symptomatic central nervous system (CNS) metastases requiring steroids~* Diagnosis of any other malignancy within 5 years prior to randomization, except for adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the breast or of the cervix, low grade prostate cancer on surveillance without any plans for treatment intervention, or prostate cancer that has been adequately treated with prostatectomy or radiotherapy and currently with no evidence of disease or symptoms.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): Avelumab plus Best Supportive Care (BSC)
- Arm B (Type: OTHER): Best Supportive Care (BSC) alone~Following the planned interim analysis for this study, eligible patients in Arm B whose cancer has not worsened and are still in the watch and wait part of the study will be given the option to receive Avelumab plus BSC. Prior to this, Arm B patients received BSC alone. All patients who choose not to receive Avelumab will be discontinued.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clofarabine, Cytarabine and Mitoxantrone (CLAM) for Relapsed or Refractory AML

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Relapsed or refractory acute myeloid leukemia (AML) after one first-line chemotherapy regimen~2. Patients aged 18 - 65 inclusively~3. European Cooperative Oncology Group (ECOG) performance status of less than 2~Exclusion Criteria:~1. Patients aged less than 18 or above 65~2. ECOG performance status of 2 or more~3. Acute promyelocytic leukaemia~4. Uncontrolled active infection~5. Uncontrolled arrhythmia~6. Altered renal dysfunction with serum creatinine \> 1.5 x ULN and/or creatinine clearance \< 50 mL/min~7. Significant neurologic (grade \> 2) or psychiatric disorder, dementia or seizures~8. Clinical symptoms suggesting active central nervous system leukemia~9. Severe complications of leukemia such as uncontrolled bleeding, pneumonia with hypoxia or shock or disseminated intravascular coagulation~10. Patients with known HIV, Hepatitis B or C infection or history of cirrhosis~11. Patients Significant hepatic dysfunction: Direct bilirubin \> 1.5 x upper limit of normal (ULN) for age; ALT or AST \> 3 x upper limit of normal (ULN) for age; Lipase \> 2.0 x upper limit of normal (ULN) for age~12. Females of childbearing potential must have a negative pregnancy test

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Clofarabine, AraC, mitoxantrone (CLAM) (Type: OTHER): This is the single arm with the intervention using Clofarabine, AraC, Mitoxantrone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Multicenter Study Comparing Docetaxel Plus Cisplatin and 5-FU to Cisplatin Plus 5-FU in Advanced Gastric Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient's consent form obtained, signed and dated before beginning specific protocol procedures.~* Gastric adenocarcinoma including adenocarcinoma of the esophagogastric junction, histologically proven.~* Measurable and/or evaluable metastatic disease; if a single metastatic lesion is the only manifestation of the disease, cytology or histology is mandatory. Locally recurrent disease is accepted provided that there is at least one measurable lesion (e.g. lymph node).~* Performance status Karnofsky index \> 70%.~* Life expectancy of more than 3 months.~* Adequate haematological and biochemistry parameters~* No prior palliative chemotherapy, previous adjuvant (and/or neo-adjuvant) chemotherapy is allowed if more than 12 months has elapsed between the end of adjuvant (or neo-adjuvant) therapy and first relapse.~Exclusion Criteria:~* Pregnant or lactating women.~* Patients (M/F) with reproductive potential not implementing adequate contraceptive measures.~* Other tumor type than adenocarcinoma (leiomyosarcoma ; lymphoma).~* Any prior palliative chemotherapy. Prior adjuvant (and/or neo-adjuvant) chemotherapy with a first relapse within 12 months from the end of adjuvant (or neo-adjuvant).~* Prior treatment with taxanes. Prior CDDP as adjuvant (and/or neo-adjuvant) chemotherapy with cumulative dose \> 300 mg/m².

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete